Study guide
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine
Key Takeaways Explain This Topic AI
Hypertension is primary (~90-95% of cases, driven by RAAS and sympathetic activation) or secondary (renal artery stenosis, aldosteronism, pheochromocytoma); chronic elevation causes LVH, heart failure, stroke, and CKD.
Heart failure is classified by ejection fraction: HFrEF (LVEF ≤40%) features systolic dysfunction, HFpEF (LVEF ≥50%) features diastolic dysfunction, and HFmrEF (41-49%) sits between; maladaptive RAAS and sympathetic drive cardiac remodeling.
Acute coronary syndrome spans unstable angina (no biomarker elevation), NSTEMI (subendocardial infarct, troponin positive), and STEMI (transmural infarct, ST elevation requiring urgent reperfusion) — all rooted in atherosclerotic plaque rupture and thrombosis.
Type 1 diabetes is autoimmune beta-cell destruction with absolute insulin deficiency; Type 2 is insulin resistance plus relative deficiency — chronic hyperglycemia drives microvascular (nephropathy, retinopathy, neuropathy) and macrovascular (CVD, stroke, PAD) complications via sorbitol, AGEs, and PKC activation.
Thyroid storm is life-threatening thyrotoxicosis with hyperthermia, tachyarrhythmia, heart failure, and altered mental status; Cushing's reflects cortisol excess, Addison's reflects primary adrenal insufficiency, and pheochromocytoma secretes catecholamines causing episodic hypertension.
Last updated: July 2026
- Cardiovascular Pathophysiology
- Hypertension
Hypertension (HTN) is sustained arterial blood pressure ≥130/80 mmHg per ACC/AHA. Primary (essential) HTN accounts for ~90-95% of cases with no identifiable cause; pathogenesis involves increased sympathetic nervous system (SNS) activity, renin-angiotensin-aldosterone system (RAAS) activation, sodium retention, and vascular remodeling. Secondary HTN has identifiable causes: renal artery stenosis, primary aldosteronism, pheochromocytoma, obstructive sleep apnea, aortic coarctation, CKD. Chronic pressure elevation produces end-organ damage : left ventricular hypertrophy (LVH), heart failure, ischemic stroke, intracerebral hemorrhage, CKD, hypertensive retinopathy.
Heart Failure
Heart Failure (HF) is a clinical syndrome of impaired ventricular filling or ejection. Heart Failure with reduced Ejection Fraction (HFrEF) (LVEF ≤40%) features systolic dysfunction — weak pump. Heart Failure with preserved Ejection Fraction (HFpEF) (LVEF ≥50%) features diastolic dysfunction — stiff ventricle with impaired relaxation. Heart Failure with mildly reduced EF (HFmrEF) (41-49%) sits between. Compensatory neurohormonal activation (RAAS, SNS, arginine vasopressin) initially supports perfusion but drives maladaptive cardiac remodeling : myocyte hypertrophy, interstitial fibrosis, chamber dilation, worsening function. Natriuretic peptides (ANP, BNP) counter-regulate but are overwhelmed.
HF Category LVEF Key Pathophysiology Guideline-Directed Therapy
HFrEF ≤40% Systolic dysfunction, dilated ventricle ARNI/ACEI/ARB + beta-blocker + MRA + SGLT2 inhibitor ± loop diuretic
HFmrEF 41-49% Mildly reduced systolic function SGLT2 inhibitor; consider ARNI/ACEI/ARB, beta-blocker, MRA
HFpEF ≥50% Diastolic dysfunction, stiff ventricle SGLT2 inhibitor; diuretic for congestion; treat HTN, AF, comorbidities
Coronary Artery Disease and Acute Coronary Syndrome
Atherosclerosis begins with endothelial injury (lipids, hypertension, smoking, hyperglycemia), LDL infiltration, oxidative modification, macrophage uptake forming foam cells and fatty streaks. Smooth muscle migration and collagen deposition produce a fibrous plaque with a lipid-rich core. Inflammatory thinning of the fibrous cap leads to plaque rupture , exposing thrombogenic contents to platelets and coagulation factors. The acute coronary syndrome (ACS) spectrum spans unstable angina (ischemia without biomarker elevation), NSTEMI (subendocardial infarction, troponin positive, no ST elevation), and STEMI (transmural infarction, ST elevation, urgent reperfusion required).
Arrhythmias
Atrial fibrillation (AF) features chaotic atrial depolarization with an irregularly irregular ventricular response and increased stroke risk from left atrial thrombus. Supraventricular tachycardia (SVT) originates above the ventricles. Ventricular tachycardia (VT) and ventricular fibrillation (VF) are life-threatening and require immediate defibrillation. Conduction abnormalities (AV block, bundle branch block) impair impulse propagation. QT prolongation predisposes to torsades de pointes — many drugs (macrolides, fluoroquinolones, antipsychotics, methadone, ondansetron) extend QT and require monitoring.
Dyslipidemia
Elevated low-density lipoprotein (LDL) is the principal atherogenic particle; high-density lipoprotein (HDL) mediates reverse cholesterol transport; triglycerides (TG) contribute modestly but very high levels (>1,000 mg/dL) risk acute pancreatitis. The LDL:HDL ratio, non-HDL cholesterol, and apolipoprotein B refine cardiovascular risk assessment, particularly in metabolic syndrome and diabetes where atherogenic remnant particles abound. Familial hypercholesterolemia (LDL receptor or PCSK9 mutations) produces severely elevated LDL and premature ASCVD, illustrating the causal role of LDL in atherogenesis.
Hypertensive Urgency and Emergency
Hypertensive urgency is BP ≥180/120 without acute end-organ damage and is managed with gradual oral lowering. Hypertensive emergency features acute target-organ damage (encephalopathy, intracerebral hemorrhage, acute pulmonary edema, aortic dissection, acute renal failure, eclampsia) and requires titratable IV therapy (nicardipine, labetalol, clevidipine, esmolol) with controlled reduction (no more than 25% in the first hour). Distinguishing urgency from emergency is essential because overly rapid correction risks ischemic stroke and acute kidney injury from autoregulation failure.
Venous Thromboembolism
Deep vein thrombosis (DVT) and pulmonary embolism (PE) arise from Virchow's triad : venous stasis, endothelial injury, and hypercoagulability. Risk factors: immobility, surgery, malignancy, pregnancy, estrogen therapy, inherited thrombophilias (factor V Leiden, prothrombin gene mutation, antithrombin deficiency).
- Endocrine Pathophysiology
- Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is autoimmune destruction of pancreatic beta-cells producing absolute insulin deficiency; it presents with polyuria, polydipsia, weight loss, and risk of diabetic ketoacidosis (DKA) . Type 2 diabetes mellitus (T2DM) begins with insulin resistance in muscle, liver, and adipose; compensatory hyperinsulinemia eventually fails as beta-cell function declines. Chronic hyperglycemia drives complications through sorbitol accumulation (aldose reductase), advanced glycation end-products (AGEs) , and protein kinase C (PKC) activation. Microvascular complications : diabetic nephropathy (glomerulosclerosis, albuminuria), retinopathy (pericyte loss, neovascularization), neuropathy (distal symmetric sensorimotor, autonomic). Macrovascular complications : coronary artery disease, stroke, peripheral arterial disease.
Thyroid Disorders
Hypothyroidism most commonly arises from Hashimoto's thyroiditis (anti-thyroid peroxidase antibodies) — fatigue, cold intolerance, bradycardia, weight gain, delayed reflexes. Hyperthyroidism commonly reflects Graves' disease (thyroid-stimulating immunoglobulin activating the TSH receptor) — heat intolerance, tachycardia, weight loss, exophthalmos. Thyroid storm is life-threatening thyrotoxicosis with hyperthermia, tachyarrhythmia, heart failure, and altered mental status requiring beta-blockade, thionamides, iodine, and glucocorticoids.
Adrenal Disorders
Cushing's syndrome reflects excess cortisol from pituitary adenoma (Cushing's disease), adrenal tumor, or exogenous steroids; central obesity, moon facies, purple striae, hyperglycemia, osteoporosis. Addison's disease is primary adrenal insufficiency from autoimmune destruction — fatigue, hypotension, hyperpigmentation, hyponatremia, hyperkalemia. Pheochromocytoma is a catecholamine-secreting tumor causing episodic hypertension with headache, diaphoresis, and palpitations.
Metabolic Syndrome and PCOS
Metabolic syndrome clusters abdominal obesity, atherogenic dyslipidemia (high TG, low HDL), hypertension, and insulin resistance, multiplying cardiovascular and diabetes risk. Polycystic ovary syndrome (PCOS) features hyperandrogenism, oligo-anovulation, polycystic ovaries, and insulin resistance, increasing T2DM and endometrial cancer risk.